Latest News

Vaxxas completes enrollment for largest clinical trial of HD-MAP for vaccine delivery February 20, 2025

Vaxxas has completed enrollment for its Phase 1 clinical trial of a vaccine against an avian influenza A (H7N9) virus with pandemic potential, delivered by the company’s proprietary high-density microarray patch.

AusBiotech launches member-only 'Spotlight' series February 20, 2025

As the peak body advocating for our members and building a thriving life sciences industry, we know we have a responsibility to share the stories that shape our sector and inspire future growth.

IDT delivers strong first-half performance following strategic pivot February 19, 2025

Australian pharmaceutical manufacturing company IDT Australia (ASX:IDT) has reported an 83 per cent increase in revenue for the first half of financial year 2025.

US FDA fast-track designation for Clarity's Cu-67 SAR-bisPSMA for prostate cancer February 19, 2025

Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced that the US FDA has granted fast-track designation for 67Cu-SAR-bisPSMA for the treatment of adult patients with a form of prostate cancer.

PYC Therapeutics successfully completes institutional component of entitlement offer February 19, 2025

CEO Dr Rohan Hockings said, “This Entitlement Offer has created an opportunity for the company to generate human safety and efficacy data for multiple drug candidates with category-leading potential in areas of major unmet patient need."

FDA grants fast-track designation for Neuren's NNZ-2591 in Pitt Hopkins syndrome February 18, 2025

The US FDA has granted fast-track designation for Neuren's NNZ-2591 for the treatment of Pitt Hopkins syndrome.

Syntara’s topical anti-fibrotic drug leads to significant normalisation of skin in established scars February 18, 2025

Clinical-stage drug development company Syntara (ASX:SNT) has announced new findings from a subgroup analysis of 14 patients from the placebo-controlled SOLARIA2 trial.

The first-ever Women in Life Sciences Leadership Summit February 18, 2025

AusBiotech is taking steps to advance gender equity in the life sciences sector by launching the inaugural Women in Life Sciences Leadership Summit.

PYC Therapeutics to raise up to $146 million to support late-stage trials February 17, 2025

PYC Therapeutics (ASX:PYC) has announced a pro-rata accelerated non-renounceable entitlement offer to eligible shareholders to raise $146 million.

Althea Group appoints new non-executive director February 17, 2025

Medicinal cannabis company Althea Group Holdings (ASX:AGH) has announced the appointment of Matt Adams as a non-executive director.

Axelia Oncology announces supply agreement for PBS-listed cancer medicine February 17, 2025

Axelia Oncology has entered into a clinical supply agreement with Regeneron to study the use of the PBS-listed PD-1 inhibitor LIBTAYO (cemiplimab) with the Australian company's investigative candidate, AXA-042.

AusBiotech welcomes national prioritisation of R&D to build a stronger Australia February 14, 2025

AusBiotech has welcomed the release of the Australian Government’s discussion paper on the Strategic Examination of R&D, underscoring the urgent need for reform to bolster the country's innovation ecosystem and global competitiveness.

Most Read

Vaxxas completes enrollment for largest clinical trial of HD-MAP for vaccine delivery

AusBiotech launches member-only 'Spotlight' series

US FDA fast-track designation for Clarity's Cu-67 SAR-bisPSMA for prostate cancer

IDT delivers strong first-half performance following strategic pivot

PYC Therapeutics successfully completes institutional component of entitlement offer

New Stories

Vaxxas completes enrollment for largest clinical trial of HD-MAP for vaccine delivery

AusBiotech launches member-only 'Spotlight' series

IDT delivers strong first-half performance following strategic pivot

US FDA fast-track designation for Clarity's Cu-67 SAR-bisPSMA for prostate cancer

PYC Therapeutics successfully completes institutional component of entitlement offer

FDA grants fast-track designation for Neuren's NNZ-2591 in Pitt Hopkins syndrome

Syntara’s topical anti-fibrotic drug leads to significant normalisation of skin in established scars

Sign In

Most Read

Vaxxas completes enrollment for largest clinical trial of HD-MAP for vaccine delivery

AusBiotech launches member-only 'Spotlight' series

US FDA fast-track designation for Clarity's Cu-67 SAR-bisPSMA for prostate cancer

IDT delivers strong first-half performance following strategic pivot

PYC Therapeutics successfully completes institutional component of entitlement offer

Follow Us

New Stories

Vaxxas completes enrollment for largest clinical trial of HD-MAP for vaccine delivery

AusBiotech launches member-only 'Spotlight' series

IDT delivers strong first-half performance following strategic pivot

US FDA fast-track designation for Clarity's Cu-67 SAR-bisPSMA for prostate cancer

PYC Therapeutics successfully completes institutional component of entitlement offer

FDA grants fast-track designation for Neuren's NNZ-2591 in Pitt Hopkins syndrome

Syntara’s topical anti-fibrotic drug leads to significant normalisation of skin in established scars